ArticleClinical, cosmetic and investigational dermatology2026
Burdens of Malignant Melanoma and Projections for 2050 in Asia: Findings from the 2023 Global Burden of Disease Study.
Article in Clinical, cosmetic and investigational dermatology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Malignant melanoma(MM) is a significant global health concern, with increasing incidence worldwide. However, comprehensive assessments of its burden in Asia remain limited. Methods: Based on the Global Burden of Disease Study (GBD) data for 2023, an analysis was conducted on the disease burden of MM across 48 countries in Asia from 1990 to 2023. The trends in the disease burden of MM were assessed using the Estimated Annual Percentage Change (EAPC). Furthermore, the Bayesian Age-Period-Cohort (BAPC) model was employed to predict the future burden of MM to 2050. Results: From 1990 to 2023, age-standardized incidence rates (ASIR) increased across most of Asia, with the most pronounced positive EAPC values observed in low- and middle-SDI regions. In contrast, high-SDI areas exhibited stable incidence rates but declining mortality and disability-adjusted life year (DALY) rates. The epicenter of the burden shifted from affluent nations to rapidly developing economies; by 2023, East Asia reported the highest absolute case numbers and prevalence. The age distribution has shifted from the 45-64 age group to those aged 65 years and older, with individuals aged 75 and above dominating both prevalence and mortality rates in East Asia. Key drivers of these trends include cumulative UV exposure, lifestyle changes, and disparities in diagnosis and treatment. The BAPC forecasts for East Asia from 2024 to 2050 predict continued increases in ASIR and prevalence, stabilization of mortality rates, and modest declines in DALYs; however, uncertainty intervals widen as the forecast horizon extends. Conclusion: Asia faces a dual challenge: rising incidence and a progressive eastward/southward burden shift to lower‑SDI countries. Effective responses require equitable, context‑specific strategies combining sun‑safety campaigns, early detection, advanced diagnostics, and affordable treatments across socioeconomic strata. Strengthening prevention, healthcare infrastructure, and surveillance is essential to reduce the long‑term human and economic impact of melanoma in the region.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.